Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Abstrato

Advances in the Diagnosis and Prognosis of Breast Cancer?s Minor Residual Lesions

Weici Liu

Breast cancer’s minor residual lesions post-treatment have posed challenges in accurate diagnosis and prognosis. This article explores recent advancements in the field that have revolutionized the assessment of these lesions. Multipara metric imaging techniques, liquid biopsies, artificial intelligence (AI), genomic profiling, and predictive models are reshaping the landscape of post-treatment management. Multipara metric imaging combines functional and morphological data for precise lesion characterization. Liquid biopsies offer non-invasive monitoring of treatment response and detection of residual cancer cells. AI-driven algorithms analyze imaging and clinical data, aiding in diagnosis and outcome prediction. Genomic profiling identifies genetic alterations influencing residual cancer cell behavior. Predictive models integrate data for recurrence likelihood estimation. While challenges persist, such as standardization and ethical considerations, these innovations hold great promise for personalized medicine and improved patient outcomes